Stockscreener 앱 받기
5.95
0.67%
-0.04
시간 외 거래:
6.06
0.11
+1.85%
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
New Taysha Gene Therapies hires receive 349,000-share stock grant - Stock Titan
RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan
BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating - moomoo.com
Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - Stock Titan
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6%Here's Why - marketbeat.com
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Yahoo Finance
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - marketbeat.com
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Australia
Why is Taysha Gene Therapies stock sliding today? - Investing.com
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView
Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA - marketbeat.com
Taysha Gene Therapies Inc (TSHA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TSHA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlig - GuruFocus
Taysha Gene Therapies Q2 2026 Earnings Call Transcript - MarketBeat
TSHA Looks 873.5% Overvalued on GF Value™ - GuruFocus
Taysha Gene Therapies Q2 Earnings Call Highlights - MarketBeat
TSHA: Completed pivotal trial dosing, secured $230M financing, and advanced toward BLA submission - TradingView
Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast - Investing.com
Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million - scanx.trade
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss - marketscreener.com
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - marketbeat.com
Taysha Gene Therapies Q2 net loss widens on higher R&D costs - TradingView
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Taysha Gene faces earnings test as Rett therapy advances By Investing.com - Investing.com Canada
Taysha Gene faces earnings test as Rett therapy advances - Investing.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies, Inc. (TSHA): Investor Outlook Reveals A Potential 108.99% Upside - DirectorsTalk Interviews
Manufacturing deal prepares Rett gene therapy for potential U.S. launch - Rett Syndrome News
Taysha Sets Aug. 11 Webcast on Rare-Disease Gene Therapies - Stock Titan
Taysha Gene Therapies (TSHA) to Announce Quarterly Earnings on Tuesday - marketbeat.com
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 - Yahoo Finance
Taysha secures commercial manufacturing deal with Catalent - Investing.com
Taysha secures commercial manufacturing deal with Catalent By Investing.com - Investing.com South Africa
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - The Manila Times
Taysha Gene Therapies, Inc. and Catalent, Inc. Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - marketscreener.com
Taysha’s Rett Gene Therapy Gets a Future Commercial Manufacturer - Stock Titan
Seven Fleet Capital Management LP Has $2.80 Million Holdings in Taysha Gene Therapies, Inc. $TSHA - marketbeat.com
Taysha Gene Therapies Inc (TSHA) Institutional Confidence - TradingKey
Taysha Gene Therapies Inc (TSHA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Time To Take A Look At Taysha: Rett Syndrome Gene Therapy Trial On Track For Key Interim Analysis - RTTNews
Taysha Gene Therapies Inc (TSHA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Healthcare of Ontario Pension Plan Trust Fund - marketbeat.com
TSHA|Taysha Gene Therapies Inc|Price:5.540|Chg%:+0.020 - TradingKey
Taysha Gene Therapies (NASDAQ:TSHA) Trading 8% HigherStill a Buy? - marketbeat.com
Taysha Gene Therapies Inc (TSHA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Taysha Gene Therapies Inc (TSHA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Taysha Gene Therapies Inc (TSHA) Cash Flow - TradingKey
Taysha Gene Therapies, Inc. $TSHA Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
TradingKey - TradingKey
Taysha Gene Therapies, Inc. Revenue Breakdown – NASDAQ:TSHA - TradingView
TSHA|Taysha Gene Therapies Inc|Price:6.215|Chg%:+0.435 - TradingKey
Taysha Gene Therapies, Inc. $TSHA Position Reduced by Affinity Asset Advisors LLC - marketbeat.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of "Buy" by Brokerages - marketbeat.com
TSHA Maintains Buy Rating -- Price Target Raised to $13.00 by Go - GuruFocus
Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $13 - Moomoo
Goldman Sachs raises Taysha Gene Therapies target to $13 - scanx.trade
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In - Yahoo Finance
Taysha Gene Therapies (TSHA) Experiences Significant Decline - GuruFocus
Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing - Moomoo
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run - The Motley Fool
0.52%
0.07%
자본화:
|
볼륨(24시간):